Experimental Treatments for Epidermolysis Bullosa

Overview

There is no cure for epidermolysis bullosa (EB), and there are no treatments designed specifically to manage the symptoms. However, with ongoing research, understanding of the cause of EB has grown. This has led to the identification of several potential treatments, and clinical trials are ongoing to assess if they can provide a benefit to patients.

EB-101

EB-101 is am investigational gene therapy being developed for the treatment of recessive dystrophic epidermolysis bullosa. EB-101 consists of a correct copy of the COL7A1 gene packaged into a retrovirus. A Phase 3 trial is currently enrolling.

Learn more

FCX-007

FCX-007 is being developed to treat recessive dystrophic epidermolysis bullosa. It is a cell-based therapy that genetically modifies a patient’s own skin cells to produce healthy copies of type 7 collagen. It is currently being tested in an ongoing Phase 1/2 trial.

Learn more